PDF herunterladen
Thromb Haemost 1987; 58(02): 778-785
DOI: 10.1055/s-0038-1645969
Original Article
Schattauer GmbH Stuttgart

Detection of Activation of the Contact System of Coagulation In Vitro and In Vivo: Quantitation of Activated Hageman Factor-C1-Inhibitor and Kallikrein-C1-Inhibitor Complexes by Specific Radioimmunoassays

J H Nuijens
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
C C M Huijbregts
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
M Cohen
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
G O Navis
*   Department of Cardio-anesthesiology, University Hospital, Utrecht, The Netherlands
,
A de Vries
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
A J M Eerenberg
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
J C Bakker
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
C E Hack
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 24. Februar 1987

Accepted after revision 29. April 1987

Publikationsdatum:
27. Juni 2018 (online)

  als PDF herunterladen  Lizenzen und Reprints

Summary

Radioimmunoassays (RIAs) for the detection of C1-inhihitor (C1-Inh) complexed to either kallikrein or activated Hageman factor (factor XIIa) are described. Kallikrein-C1-Inh or factor XIIa-C1-Inh complexes were bound to Scpharosc to which monospecific antibodies against (pre)kallikrein or factor XII, respectively, were coupled. Bound complexes were subsequently detected by an incubation with affinity purified 125I-labeled antibodies against Ci-Inh. These RIAs were used to detect activation of the contact system of coagulation in vitro and in vivo. Addition of dextran sulfate (DXS) (20 μg/ml) to fresh plasma resulted at 37° C in the rapid generation of amidolytic kallikrein activity, which was maximal after 1 to 2 min of incubation and subsequently decreased within a few minutes. The generation of kallikrein activity coincided with the appearance of both kallikrein-C1-Inh and factor XIIa-C1-Inh complexes. However, in contrast to kallikrein activity, both types of complexes remained detectable in the incubation mixtures during the incubation period. Experiments with purified kallikrein, C1-Inh and partly purified β-factor XIIa, and activation experiments in plasmas deficient in either factor XII or prekallikrein, demonstrated the specificity of both RIAs. The minimal amount of DXS that resulted in the generation of measurable amounts of both types of complexes in plasma was 2-3 μg per ml. Similar experiments with kaolin showed that with limiting amounts of activator (1-2 mg/ ml), only kallikrein-C1-Inh complexes were detected in plasma. When larger amounts of kaolin were added to plasma, factor XIIa-C1-Inh complexes were additionally detected in plasma. In plasma samples obtained from healthy donors under conditions that prevented activation of the contact system in vitro, very low levels of both factor XIIa-C1-Inh and kallikrein-C1-Inh complexes were measured, representing approximately 0.3% activation of both factor XII and prekallikrein. In serial plasma samples from a patient with adult respiratory distress syndrome, increased levels of both types of complexes were detected. The radioimmunoassays described in this paper provide useful tools to detect activation of the contact system in vitroas well as in vivo.

Keywords

C1-Inhibitor - Factor XIIa - Kallikrein
 

  • References

  • 1 Cochrane CG, Griffin JH. The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol 1982; 33: 241-306
    PubMedGoogle Scholar
  • 2 Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 601-613
    PubMedGoogle Scholar
  • 3 Revak SD, Cochrane CG, Griffin JH. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein or high molecular weight kininogen. J Clin Invest 1977; 59: 1167-1175
    CrossrefPubMedGoogle Scholar
  • 4 Espana F, Ratnoff OD. The role of prekallikrein and high-molecular-weight kininogen in the contact activation of Hageman factor (factor XII) by sulfatides and other agents. J Lab Clin Med 1983; 102: 487-499
    PubMedGoogle Scholar
  • 5 Bouma BN, Miles LA, Beretta G, Griffin JH. Human plasma prekallikrein. Study of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry 1980; 19: 1151-1160
    CrossrefPubMedGoogle Scholar
  • 6 Matheson RT, Miller DR, Lacombe M-J, Han YN, Iwanaga S, Kato H, Wuepper KD. Flaujeac Factor Deficiency. Reconstitution with highly purified bovine high molecular weight kininogen and delineation of a new permeability-enhancing peptide released by plasma kallikrein from bovine high molecular-weight kininogen. J Clin Invest 1976; 58: 1395-1406
    CrossrefPubMedGoogle Scholar
  • 7 Mason JW, Colman RW. The role of Hageman factor in disseminated intravascular coagulation induced by septicemia, neoplasia, or liver disease. Thromb Diath Haemorrh 1971; 26: 325-331
    PubMedGoogle Scholar
  • 8 Colman RW, Edclman R, Scott CF. Gilman RTF Plasma kallikrein activation and inhibition during typhoid fever. J Clin Invest 1978; 61: 287-296
    CrossrefPubMedGoogle Scholar
  • 9 Kellermeyer RW, Breckenridge RT. The inflammatory process in acute gouty arthritis. II. The presence of Hageman factor and plasma thromboplastin antecedent in synovial fluid. J Lab Clin Med 1966; 67: 455-460
    PubMedGoogle Scholar
  • 10 Bleeker WK, Van Rosevelt RF, Ufkes J GR, Loos JA, Van Mourik JA, Bakker JC. Hypotensive effects of plasma protein fraction. The relation between prekallikrein activator, bradykinin generation, and blood pressure in an animal model. J Lab Clin Med 1982; 100: 540-557
    PubMedGoogle Scholar
  • 11 Forbes CD, Pensky J, Ratnoff OD. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedant by purified scrum C, inactivator. J Lab Clin Med 1970; 76: 809-815
    PubMedGoogle Scholar
  • 12 De Agostini A, Lijnen HR, Pixley RA, Colman RW, Schapira M. Inactivation of Factor XTT active fragment in normal plasma, Predominant role of Crmhibitor. J Clin invest 1984; 73: 1542-1549
    CrossrefPubMedGoogle Scholar
  • 13 Pixley RA, Schapira M, Colman RW. The regulation of human Factor Xlla by plasma proteinase inhibitors. J Biol Chem 1985; 260: 1723-1729
    PubMedGoogle Scholar
  • 14 Gigli I, Mason JW, Colman RW, Austen KF. Interaction of plasma kallikrein with the Q inhibitor. J Immunol 1970; 104: 574-581
    PubMedGoogle Scholar
  • 15 Schapira M, Scott CF, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 1982; 69: 462-468
    CrossrefPubMedGoogle Scholar
  • 16 Van der Graaf F, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest 1983; 71: 149-158
    CrossrefPubMedGoogle Scholar
  • 17 Lewin MF, Kaplan AP, Harpel PC. Studies of Q inactivator-plasma kallikrein complexes in purified systems and in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J Biol Chem 1983; 258: 6415-6421
    PubMedGoogle Scholar
  • 18 Kaplan AP, Gruber B, Harpel PC. Assessment of Hageman Factor activation in human plasma: quantitation of activated Hageman factor-Crinactivator complexes by an enzyme-linked differential antibody immunosorbent assay. Blood 1985; 66: 636-641
    PubMedGoogle Scholar
  • 19 Hack CE, Hannema AJ, Eerenberg-Belmer A JM, Out TA, Aalberse RC. A Crinhibitor-complex assay (INCA): a method to detect Q activation in vitro and in vivo . J Immunol 1981; 127: 1450-1453
    PubMedGoogle Scholar
  • 20 Nagase H, Barrett AJ. Human plasma kallikrein. A rapid purification method with high yield. Biochem J 1981; 193: 187-192
    CrossrefPubMedGoogle Scholar
  • 21 Bakker JC, De Vries-Van Rossen A, Radema H, Bleeker W, Ufkes J GR, Van Rosevelt RF, Van Mourik JA. Identification of a bradykinin-generating hypotensive substance in plasma protein fraction; prekallikrein activator. In: Kinins III, Adv Exp Med Biol. Fritz H, Back N, Dietze G, Haberland GL. (eds.) Plenum Press; New York/London: 1983. 156B 1091-1097
    Google Scholar
  • 22 Pensky J, Levy LR, Lepow IH. Partial purification of a serum inhibitor of Cresterase. J Biol Chem 1961; 236: 1674-1679
    PubMedGoogle Scholar
  • 23 Sim RB, Arlaud G, Colomb MG. Crinhibitor-dependent dissociation of human complement Q bound to immune complexes. Biochem J 1979; 179: 449-457
    CrossrefPubMedGoogle Scholar
  • 24 Scott CF, Schapira M, James HL, Cohen AB, Colman RW. Inactivation of Factor XIa by plasma protease inhibitors. Predominant role of arprotease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest 1982; 69: 844-852
    CrossrefPubMedGoogle Scholar
  • 25 Schreiber AD, Kaplan AP, Austen KF. Plasma inhibitors of the components of the fibrinolytic pathway in man. J Clin Invest 1973; 52: 1394-1401
    CrossrefPubMedGoogle Scholar
  • 26 Ziccardi RJ, Cooper MR. Active dissambly of the first complement component, Q, by Q inactivator. J Immunol 1979; 123: 788-792
    PubMedGoogle Scholar
  • 27 Cooper NR, Nemerow GR, Mayes TJ. Methods to detect and quantitate complement activation. Springer Semin Immunopathol 1983; 6: 195-212
    PubMedGoogle Scholar
  • 28 Ziccardi RJ, Cooper NR. Development of an immunochemical test to assess Q inactivator function in human serum and its use for the diagnosis of hereditary angioedema. Clin Immunol Immunopathol 1980; 15: 465-471
    CrossrefPubMedGoogle Scholar
  • 29 Kluft C. Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein. J Lab Clin Med 1978; 91: 83-95
    PubMedGoogle Scholar
  • 30 Revak SD, Cochrane CG, Bouma BN, Griffin JH. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med 1978; 147: 719-729
    CrossrefPubMedGoogle Scholar
  • 31 Griffin JH. The contact phase of blood coagulation. In: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (eds.) Churchill Livingstone; 1981. pp 84-97
    Google Scholar
  • 32 Dunn JT, Silverberg M, Kaplan AP. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem 1982; 257: 1779-1784
    PubMedGoogle Scholar
  • 33 Velasco F, Torres A, Guerrero A, Andres P, Guerrero R, Aljama P, Alvarez F. Behavior of the contact phase of blood coagulation in the adult respiratory distress syndrome (ARDS). Thromb Haemostas 1986; 55: 357-360
    PubMedGoogle Scholar
  • 34 Schapira M, Despland E, Scott CF, Boxer LA, Colman RW. Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 1982; 69: 1199-1202
    CrossrefPubMedGoogle Scholar
  • 35 Wachtfogel YT, Kucich U, James HL, Scott CF, Schapira M, Zimmerman M, Cohen AB, Colman RW. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 1983; 72: 1672-1677
    CrossrefPubMedGoogle Scholar
  • 36 McGuire WW, Spragg RG, Cohen AB, Cochrane CG. Studies on the pathogenesis of the adult respiratory distress syndrome. J clin Invest 1982; 69: 543-553
    CrossrefPubMedGoogle Scholar